Introduction to the Burden of Recurrent Cystitis and Rationale for Prevention

This educational summit, supported by an independent grant from OM/Vifor Pharma, brought together experts in the field of urology and gynaecology from Europe and Latin America to meet and discuss the cutting edge management of patients suffering from recurrent urinary tract infections (rUTIs). The meeting included plenary lectures as well as workshops and interactive sessions, allowing delegates and presenters to debate the most pressing international and local issues in the field.

50% of women experience at least one UTI in their lifetime; 25% and 44% of these patients will suffer recurrence of infection within 6 months and 1 year, respectively. It is estimated that rUTI affects up to 10% of otherwise healthy women.1 Data from epidemiologic studies suggest that each episode of acute cystitis in young women is associated with approximately 6.1 days of symptoms, 2.9 days of restricted activity, 1.2 days of inability to attend classes or work, and 0.4 days of bed rest. This may represent a burden for the patients. Furthermore, the management of each repeated infection leads to healthcare system expenditures. Given the level of prevalence and recurrence, assessment of the burden of UTI at both an individual and societal level and the identification of prophylactic measures to ameliorate this burden are essential for the effective management of rUTI.